{'fraction_non_alphanumeric': 0.027450980392156862, 'fraction_numerical': 0.023529411764705882, 'mean_word_length': 4.873563218390805, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Studies of EN-1639A (naltrexone): a new narcotic antagonist.

The narcotic antagonist EN-1639A (naltrexone) was studied in 37 heroin addicts and found to be clinically useful, with a low incidence of side effects, lack of toxicity, high degree of acceptability to the patient, and capacity to antagonize the euphoric effects of heroin for up to 72 hours after a single oral dose. These findings provide a basis for expanding studies of the clinical efficacy of naltrexone in the treatment of opiate dependence.